In a large retrospective study, radical prostatectomy was significantly associated with a survival advantage among men with high-risk prostate cancer compared with external beam radiation therapy.
Stereotactic body radiotherapy more than doubled the complete response rate.
A 6-month course of androgen suppression added to external beam radiation therapy increased long-term event-free and disease-free survival compared with EBRT alone, a study found.
Low-risk patients did not appear to benefit from adjuvant radiation.
Biopsy Gleason patterns 4+5, 5+4, and 5+5 should be given separate consideration in pretreatment risk stratification, according to investigators.
Radiation therapy directed at the primary prostate tumor decreased mortality risk by 31% in adjusted analyses, a study found.
In a small phase 2 trial involving men with intermediate-risk prostate cancer, a single ultra-high dose of radiation was safe and comparable to curative hypofractionated stereotactic body radiation therapy in tumor control and quality-of-life measures.
Investigators found that the odds of locoregional recurrence of muscle-invasive bladder cancer following radical cystectomy depend on disease risk category.
The overall and failure-free survival benefit of adding prostate radiation therapy to standard of care for metastatic prostate cancer declines with increasing number of bone metastases, a study found.
A cancer center in New York City safely managed patients with localized prostate cancer during the height of the COVID-19 pandemic in 2020, providing insights for handling a second COVID-19 wave.
